These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 23927827

  • 1. Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines.
    Mokhtari RB, Kumar S, Islam SS, Yazdanpanah M, Adeli K, Cutz E, Yeger H.
    BMC Cancer; 2013 Aug 08; 13():378. PubMed ID: 23927827
    [Abstract] [Full Text] [Related]

  • 2. Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane.
    Bayat Mokhtari R, Baluch N, Morgatskaya E, Kumar S, Sparaneo A, Muscarella LA, Zhao S, Cheng HL, Das B, Yeger H.
    BMC Cancer; 2019 Aug 30; 19(1):864. PubMed ID: 31470802
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN).
    Islam SS, Mokhtari RB, Akbari P, Hatina J, Yeger H, Farhat WA.
    Target Oncol; 2016 Apr 30; 11(2):209-27. PubMed ID: 26453055
    [Abstract] [Full Text] [Related]

  • 4. Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis.
    Mokhtari RB, Qorri B, Baluch N, Sparaneo A, Fabrizio FP, Muscarella LA, Tyker A, Kumar S, Cheng HM, Szewczuk MR, Das B, Yeger H.
    Oncotarget; 2021 Jul 20; 12(15):1470-1489. PubMed ID: 34316328
    [Abstract] [Full Text] [Related]

  • 5. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma.
    Bayat Mokhtari R, Baluch N, Ka Hon Tsui M, Kumar S, S Homayouni T, Aitken K, Das B, Baruchel S, Yeger H.
    BMC Cancer; 2017 Feb 24; 17(1):156. PubMed ID: 28235409
    [Abstract] [Full Text] [Related]

  • 6. Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.
    Somnay Y, Simon K, Harrison AD, Kunnimalaiyaan S, Chen H, Kunnimalaiyaan M.
    Anticancer Drugs; 2013 Jan 24; 24(1):66-72. PubMed ID: 23147412
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.
    Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G, Berdondini L, Rea F, degli Uberti EC.
    Endocr Relat Cancer; 2010 Sep 24; 17(3):719-29. PubMed ID: 20554786
    [Abstract] [Full Text] [Related]

  • 12. Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways.
    Bijangi-Vishehsaraei K, Reza Saadatzadeh M, Wang H, Nguyen A, Kamocka MM, Cai W, Cohen-Gadol AA, Halum SL, Sarkaria JN, Pollok KE, Safa AR.
    J Neurosurg; 2017 Dec 24; 127(6):1219-1230. PubMed ID: 28059653
    [Abstract] [Full Text] [Related]

  • 13. Mastocytes, autofluorescent and silver reducing elements in bronchial carcinoids.
    Gloor E, Campiche M, Baumann RP.
    Virchows Arch A Pathol Pathol Anat; 1972 Dec 24; 357(1):19-28. PubMed ID: 4628348
    [No Abstract] [Full Text] [Related]

  • 14. Pulmonary vasodilation by acetazolamide during hypoxia is unrelated to carbonic anhydrase inhibition.
    Höhne C, Pickerodt PA, Francis RC, Boemke W, Swenson ER.
    Am J Physiol Lung Cell Mol Physiol; 2007 Jan 24; 292(1):L178-84. PubMed ID: 16936246
    [Abstract] [Full Text] [Related]

  • 15. The molecular pathogenesis and management of bronchial carcinoids.
    Cakir M, Grossman A.
    Expert Opin Ther Targets; 2011 Apr 24; 15(4):457-91. PubMed ID: 21275849
    [Abstract] [Full Text] [Related]

  • 16. Carbonic anhydrase II mediates malignant behavior of pulmonary neuroendocrine tumors.
    Zhou Y, Mokhtari RB, Pan J, Cutz E, Yeger H.
    Am J Respir Cell Mol Biol; 2015 Feb 24; 52(2):183-92. PubMed ID: 25019941
    [Abstract] [Full Text] [Related]

  • 17. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity.
    Laitinen KL, Soini Y, Mattila J, Pääkkö P.
    Cancer; 2000 Apr 01; 88(7):1590-8. PubMed ID: 10738217
    [Abstract] [Full Text] [Related]

  • 18. Combination cisplatin and sulforaphane treatment reduces proliferation, invasion, and tumor formation in epidermal squamous cell carcinoma.
    Kerr C, Adhikary G, Grun D, George N, Eckert RL.
    Mol Carcinog; 2018 Jan 01; 57(1):3-11. PubMed ID: 28796401
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
    Kidd M, Schally AV, Pfragner R, Malfertheiner MV, Modlin IM.
    Cancer; 2008 Mar 15; 112(6):1404-14. PubMed ID: 18224665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.